Stocktoria
Anika Therapeutics, Inc. ANIK
Anika Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M | $130.5M | $114.6M | $105.6M | $113.4M | $103.4M |
| Gross profit | $63.8M | $76.0M | $82.5M | $73.2M | $82.9M | $69.0M | $85.9M | $74.3M | — | — |
| R&D expense | $25.8M | $25.5M | $21.8M | $18.3M | $27.3M | $23.4M | $16.7M | $18.2M | $18.8M | $10.7M |
| SG&A expense | $49.1M | $55.6M | $59.9M | $51.2M | $74.1M | $60.1M | $35.0M | $34.3M | $21.5M | $18.0M |
| Operating income | -$11.1M | -$5.1M | $844,000 | $3.7M | $2.6M | -$28.3M | $34.2M | $21.7M | $45.7M | $50.6M |
| Income tax | $672,000 | $6.1M | $6.6M | $2.1M | -$1.7M | -$4.6M | $8.9M | $4.5M | $14.4M | $18.3M |
| Net income | -$10.9M | -$56.4M | -$82.7M | -$14.9M | $4.1M | -$24.0M | $27.2M | $18.7M | $31.8M | $32.5M |
| EPS (diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 | $1.89 | $1.27 | $2.11 | $2.15 |
| Operating cash flow | $11.2M | $5.4M | -$1.8M | $4.4M | $8.4M | $13.1M | $37.0M | $34.9M | $40.8M | $24.4M |
| Free cash flow | $4.4M | -$2.3M | -$7.2M | -$3.1M | $3.3M | $11.4M | $34.2M | $30.3M | $31.8M | $10.4M |
| Cash & equivalents | $57.5M | $55.6M | $68.7M | $86.3M | $94.4M | $95.8M | $157.5M | $89.0M | $133.3M | $104.3M |
| Inventory | $18.8M | $23.8M | $24.4M | $39.8M | $36.0M | $46.2M | $22.0M | $21.3M | $22.0M | $16.0M |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M | $365.6M | $330.7M | $279.0M | $282.6M | $240.2M |
| Shareholders' equity | $143.5M | $154.0M | $212.3M | $285.6M | $287.1M | $272.4M | $288.4M | $263.6M | $263.5M | $222.8M |
Growth · year-over-year · Revenue CAGR 1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -5.9% | -0.7% | +6.1% | -23.0% | +13.3% | +13.8% | +8.6% | -6.9% | +9.7% | +11.2% |
| Net income growth | — | — | — | -459.4% | — | -188.2% | +45.2% | -41.2% | -2.2% | +5.8% |
| EPS growth | — | — | — | -464.3% | — | -189.4% | +48.8% | -39.8% | -1.9% | +7.0% |
| Free cash flow growth | — | — | — | -194.6% | -71.5% | -66.5% | +12.9% | -4.9% | +205.1% | -66.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.